Regional differences in alcohol-related mortality might reflect strong socioeconomic differences between regions. The present study examines the contribution of education, unemployment, income and minority proportion on regional differences in alcohol-related mortality for inhabitants aged 20-64 years. Linear regression analysis and a non-parametric regression tree analysis were used separately for males and females. The unemployment rate and low education appeared as important determinants of regional alcohol-related mortality, while the proportion of Roma and income were not significantly associated with alcohol-related mortality among males in Slovak districts. A district's unemployment rate was assumed to be the strongest predictor of the outcome measure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.healthplace.2011.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Real-world analysis of acamprosate use in patients with cirrhosis and alcohol-associated hepatitis.
BMJ Open Gastroenterol
December 2024
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Objective: Preventing return to alcohol is of critical importance for patients with alcohol-related cirrhosis and/or alcohol-associated hepatitis. Acamprosate is a widely used treatment for alcohol use disorder (AUD). We assessed the impact of acamprosate prescription in patients with advanced liver disease on abstinence rates and clinical outcomes.
View Article and Find Full Text PDFPeri-operative identification and management of patients with unhealthy alcohol intake.
Anaesthesia
January 2025
Consultant, Department of Peri-operative Medicine, University College London Hospitals NHS Trust, London, UK.
Introduction: This consensus statement gives practical advice for the safe management of patients with harmful alcohol intake undergoing elective and emergency surgery. The wide spectrum of alcohol-related organ dysfunction observed in this cohort of patients may have a profound impact on care, and the additional effects of alcohol withdrawal may further exacerbate postoperative morbidity and mortality.
Methods: A working party was assembled based on clinical and/or academic expertise in the area.
Morbid Obesity and Liver Transplant.
Transplant Proc
January 2025
Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, Bilbao, Spain. Electronic address:
Background: The progressive increase in the prevalence of morbid obesity (MO) in the general population is a pressing issue. This rise in MO has also been observed in patients with liver disease who are candidates for liver transplantation (LT).
Methods: A retrospective study of a single-center series was conducted to analyze the impact of MO on morbidity, mortality, and patient survival after LT.
The global, regional, and national alcohol-related colorectal cancer burden and forecasted trends: results from the global burden of disease study 2021.
Front Nutr
December 2024
Department of Oncology, Shuguang Anhui Hospital Affiliated to Shanghai University of Traditional Chinese Medicine (The First Affiliated Hospital West District of Anhui University of Chinese Medicine), Hefei, China.
Background: The mortality of colorectal cancer (CRC) is increasing year by year and poses a significant global health burden. Many studies have demonstrated that alcohol consumption is an important risk factor for CRC and is closely associated with malignant metastasis in CRC patients, which in turn leads to a poor prognosis.
Methods: This study aimed to quantify the global, regional, and national burden of alcohol-related CRC between 1990 and 2021.
Repurposing of Antiplatelet Agent: Cilostazol for the Treatment of Alcohol-Related Liver Disease.
Gut Liver
January 2025
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Alcohol-related liver disease (ALD) is a serious global health concern, characterized by liver inflammation and progressive fibrosis. There are no Food and Drug Administration-approved drugs, thus effective treatments are needed. Severe alcoholic hepatitis (AH) is the most severe manifestation of ALD, with a 28-day mortality rate ranging from 20% to 50%.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!